Works by Shah, Nirav N.

Results: 53
    1
    2

    Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis.

    Published in:
    Oncologist, 2019, v. 24, n. 7, p. 955, doi. 10.1634/theoncologist.2018-0538
    By:
    • Bair, Steven M.;
    • Strelec, Lauren E.;
    • Feldman, Tatyana A.;
    • Ahmed, Gulrayz;
    • Armand, Philippe;
    • Shah, Nirav N.;
    • Singavi, Arun N.;
    • Reddy, Nishitha;
    • Khan, Nadia;
    • Andreadis, Charalambos;
    • Vu, Khoan;
    • Huntington, Scott F.;
    • Giri, Smith;
    • Ujjani, Chaitra;
    • Howlett, Christina;
    • Faheem, Malik;
    • Youngman, Matthew R.;
    • Nasta, Sunita D.;
    • Landsburg, Daniel J.;
    • Schuster, Stephen J.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10

    Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis.

    Published in:
    Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0261-1
    By:
    • Shah, Nirav N.;
    • Ahn, Kwang Woo;
    • Litovich, Carlos;
    • Sureda, Anna;
    • Kharfan-Dabaja, Mohamed A.;
    • Awan, Farrukh T.;
    • Ganguly, Siddhartha;
    • Gergis, Usama;
    • Inwards, David;
    • Karmali, Reem;
    • Lazaryan, Alexsandr;
    • Lekakis, Lazaros;
    • Munshi, Pashna;
    • Nathan, Sunita;
    • Saad, Ayman A.;
    • Solh, Melhem;
    • Steinberg, Amir;
    • Vij, Ravi;
    • Wood, William A.;
    • Fenske, Timothy S.
    Publication type:
    Article
    11
    12

    P636: A FIRST‐IN‐HUMAN PHASE 1 STUDY OF ORAL LOXO‐338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000969448.21678.5f
    By:
    • Kwiatek, Michal;
    • Subramanian Guru Murthy, Guru;
    • Hoffmann, Marc;
    • Roeker, Lindsey;
    • Tessoulin, Benoit;
    • Danilov, Alexey;
    • Alencar, Alvaro J.;
    • Shah, Nirav N.;
    • Ghesquieres, Herve;
    • Le Gouill, Steven;
    • Jurczak, Wojciech;
    • R. Mato, Anthony;
    • Patel, Vishalkumar;
    • Guo‐Avrutin, Yingying;
    • Pauff, James M.;
    • Kazmierczak, Maciej
    Publication type:
    Article
    13
    14

    S224: HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967808.60614.fc
    By:
    • Jacobs, Ryan;
    • Nair, Ranjit;
    • Cho, Seok‐Goo;
    • Devata, Sumana;
    • Gaballa, Sameh;
    • Yoon, Dok Hyun;
    • Stevens, Don;
    • Kim, Jin Seok;
    • Shah, Nirav N;
    • Brennan, Denise Marie;
    • Law, Jason;
    • Lesley, Robin;
    • Chen, Rob;
    • Forcina, Alessandra;
    • Buelow, Ben;
    • Hou, Jing‐Zhou
    Publication type:
    Article
    15

    P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT.

    Published in:
    2023
    By:
    • Jurczak, Wojciech;
    • Luigi Zinzani, Pier;
    • Eyre, Toby A.;
    • Cheah, Chan Y.;
    • Ujjani, Chaitra S.;
    • Izutsu, Koji;
    • MA, Shuo;
    • Flinn, Ian;
    • Alencar, Alvaro J.;
    • Lewis, David;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Munir, Talha;
    • Zelenetz, Andrew D.;
    • Balbas, Minna;
    • Tsai, Donald E.;
    • Wang, Chunxiao;
    • Wang, Michael L.;
    • Shah, Nirav N.
    Publication type:
    Abstract
    16
    17

    S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY.

    Published in:
    2023
    By:
    • Brown, Jennifer R.;
    • Desikan, Sai Prasad;
    • Nguyen, Bastien;
    • Won, Helen;
    • Tantawy, Shady;
    • Mcneely, Samuel Clark;
    • Marella, Narasimha;
    • Ebata, Kevin;
    • Woyach, Jennifer;
    • Patel, Krish;
    • Tam, Constantine;
    • Eyre, Toby;
    • Cheah, Chan;
    • Shah, Nirav N;
    • Ghia, Paolo;
    • Jurczak, Wojciech;
    • Balbas, Minna;
    • Nair, Binoj;
    • Abada, Paolo;
    • Wang, Chunxiao
    Publication type:
    Abstract
    18
    19
    20
    21
    22
    23
    24
    25

    Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation.

    Published in:
    2018
    By:
    • Knight, Jennifer M.;
    • Kerswill, Stephanie A.;
    • Hari, Parameswaran;
    • Cole, Steve W.;
    • Logan, Brent R.;
    • D'Souza, Anita;
    • Shah, Nirav N.;
    • Horowitz, Mary M.;
    • Stolley, Melinda R.;
    • Sloan, Erica K.;
    • Giles, Karen E.;
    • Costanzo, Erin S.;
    • Hamadani, Mehdi;
    • Chhabra, Saurabh;
    • Dhakal, Binod;
    • Rizzo, J. Douglas
    Publication type:
    journal article
    26

    The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.

    Published in:
    Blood & Lymphatic Cancer: Targets & Therapy, 2020, v. 10, p. 1, doi. 10.2147/BLCTT.S262592
    By:
    • Ujjani, Chaitra;
    • Mato, Anthony;
    • Hill, Brian T;
    • Allan, John N;
    • Lansigan, Frederick;
    • Jacobs, Ryan;
    • Skarbnik, Alan;
    • Tuncer, Hande;
    • Pagel, John;
    • Brander, Danielle;
    • Cheson, Bruce;
    • Barr, Paul;
    • Roeker, Lindsey E;
    • Pu, Jeffrey;
    • Shah, Nirav N;
    • Goy, Andre;
    • Schuster, Stephen J;
    • Lamanna, Nicole;
    • Sehgal, Alison;
    • Tam, Constantine S
    Publication type:
    Article
    27
    28
    29

    Rare Germline Variants in Chordoma-Related Genes and Chordoma Susceptibility.

    Published in:
    Cancers, 2021, v. 13, n. 11, p. 2704, doi. 10.3390/cancers13112704
    By:
    • Yepes, Sally;
    • Shah, Nirav N.;
    • Bai, Jiwei;
    • Koka, Hela;
    • Li, Chuzhong;
    • Gui, Songbai;
    • McMaster, Mary Lou;
    • Xiao, Yanzi;
    • Jones, Kristine;
    • Wang, Mingyi;
    • Vogt, Aurelie;
    • Zhu, Bin;
    • Hutchinson, Amy;
    • Yeager, Meredith;
    • Hicks, Belynda;
    • Carter, Brian;
    • Freedman, Neal D.;
    • Beane-Freeman, Laura;
    • Chanock, Stephen J.;
    • Zhang, Yazhuo
    Publication type:
    Article
    30

    Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.

    Published in:
    Acta Haematologica, 2025, v. 148, n. 2, p. 180, doi. 10.1159/000539587
    By:
    • Roeker, Lindsey E.;
    • Coombs, Catherine C.;
    • Shah, Nirav N.;
    • Jurczak, Wojciech;
    • Woyach, Jennifer A.;
    • Cheah, Chan Y.;
    • Patel, Krish;
    • Maddocks, Kami;
    • Wang, Yucai;
    • Zinzani, Pier Luigi;
    • Munir, Talha;
    • Koh, Youngil;
    • Thompson, Meghan C.;
    • Muehlenbein, Catherine E.;
    • Wang, Chunxiao;
    • Sizelove, Richard;
    • Abhyankar, Sarang;
    • Hasanabba, Safarulla;
    • Tsai, Donald E.;
    • Eyre, Toby A.
    Publication type:
    Article
    31
    32

    Chimeric antigen receptor and bispecific T‐cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.

    Published in:
    British Journal of Haematology, 2024, v. 204, n. 3, p. 887, doi. 10.1111/bjh.19244
    By:
    • Hammons, Lindsay;
    • Haider, Shabi;
    • Portuguese, Andrew J.;
    • Banerjee, Rahul;
    • Szabo, Aniko;
    • Pasquini, Marcelo;
    • Chhabra, Saurabh;
    • Radhakrishnan, Sabarinath;
    • Mohan, Meera;
    • Narra, Ravi;
    • Dong, Jing;
    • Janz, Siegfried;
    • Shah, Nirav N.;
    • Hamadani, Mehdi;
    • D'Souza, Anita;
    • Hari, Parameswaran;
    • Dhakal, Binod
    Publication type:
    Article
    33
    34
    35

    R‐CHOP <italic>versus</italic> dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis.

    Published in:
    British Journal of Haematology, 2018, v. 180, n. 4, p. 534, doi. 10.1111/bjh.15051
    By:
    • Shah, Nirav N.;
    • Szabo, Aniko;
    • Huntington, Scott F.;
    • Epperla, Narendranath;
    • Reddy, Nishitha;
    • Ganguly, Siddhartha;
    • Vose, Julie;
    • Obiozor, Cynthia;
    • Faruqi, Fahad;
    • Kovach, Alexandra E.;
    • Costa, Luciano J.;
    • Xaiver, Ana C.;
    • Okal, Ryan;
    • Kanate, Abraham S.;
    • Ghosh, Nilanjan;
    • Kharfan‐Dabaja, Mohamed A.;
    • Strelec, Lauren;
    • Hamadani, Mehdi;
    • Fenske, Timothy S.;
    • Calzada, Oscar
    Publication type:
    Article
    36
    37
    38
    39
    40
    41

    Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e495, doi. 10.1016/j.clml.2022.01.010
    By:
    • Mohan, Meera;
    • Nagavally, Sneha;
    • Shah N, Nirav N;
    • Michaelis, Laura;
    • Chhabra, Saurabh;
    • Souza, Anita D;
    • Abedin, Sameem;
    • Runaas, Lyndsey;
    • Guru Murthy, Guru Subramanian;
    • Longo, Walter;
    • Hamadani, Mehdi;
    • Dhakal, Binod;
    • Hari, Parameswaran;
    • Fenske, Timothy S
    Publication type:
    Article
    42

    ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S378, doi. 10.1016/S2152-2650(21)01863-2
    By:
    • Cohen, Jonathon B.;
    • Shah, Nirav N.;
    • Alencar, Alvaro J.;
    • Gerson, James N.;
    • Patel, Manish R.;
    • Fahkri, Bita;
    • Jurczak, Wojciech;
    • Tan, Xuan N.;
    • Lewis, Katharine L.;
    • Fenske, Timothy S.;
    • Coombs, Catherine C.;
    • Flinn, Ian;
    • Lewis, David J.;
    • Gouill, Stephen Le;
    • Palomba, M Lia;
    • Woyach, Jennifer A.;
    • Pagel, John M.;
    • Lamanna, Nicole;
    • Barve, Minal A.;
    • Ghia, Paolo
    Publication type:
    Article
    43

    CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    44

    Poster: ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S241, doi. 10.1016/S2152-2650(21)01513-5
    By:
    • Cohen, Jonathon B.;
    • Shah, Nirav N.;
    • Alencar, Alvaro J.;
    • Gerson, James N.;
    • Patel, Manish R.;
    • Fahkri, Bita;
    • Jurczak, Wojciech;
    • Tan, Xuan N.;
    • Lewis, Katharine L.;
    • Fenske, Timothy S.;
    • Coombs, Catherine C.;
    • Flinn, Ian;
    • Lewis, David J.;
    • Le Gouill, Stephen;
    • Palomba, M. Lia;
    • Woyach, Jennifer A.;
    • Pagel, John M.;
    • Lamanna, Nicole;
    • Barve, Minal A.;
    • Ghia, Paolo
    Publication type:
    Article
    45

    Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01392-6
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G.;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    46

    Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01273-8
    By:
    • Coombs, Catherine C.;
    • Pagel, John M.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Woyach, Jennifer A.;
    • Wierda, William G.;
    • Cheah, Chan Y.;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David J.;
    • Gerson, James N.;
    • Alencar, Alvaro;
    • Taylor, Justin;
    • Abdel-Wahab, Omar;
    • Ghia, Paolo
    Publication type:
    Article
    47
    48
    49

    Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study.

    Published in:
    Acta Haematologica Polonica, 2022, v. 53, n. A, p. 33
    By:
    • Jurczak, Wojciech;
    • Mato, Anthony;
    • Pagel, John;
    • Coombs, Catherine C.;
    • Shah, Nirav N.;
    • Lamanna, Nicole;
    • Lech-Maranda, Ewa;
    • Eyre, Toby A.;
    • Munir, Talha;
    • Woyach, Jennifer A.;
    • Wierda, William G.;
    • Cheah, Chan Y.;
    • Cohen, Jonathon;
    • Roeker, Lindsey;
    • Patel, Manish R.;
    • Fakhri, Bita;
    • Barve, Minal A.;
    • Tam, Constantine S.;
    • Lewis, David;
    • Gerson, James N.
    Publication type:
    Article
    50

    Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01250-8
    By:
    • Karmali, Reem;
    • Shouse, Geoffrey;
    • Torka, Pallawi;
    • Moyo, Tamara K.;
    • Romancik, Jason;
    • Barta, Stefan K.;
    • Bhansali, Rahul;
    • Cohen, Jonathon B.;
    • Shah, Nirav N.;
    • Zurko, Joanna;
    • Kenkre, Vaishalee P.;
    • Hess, Brian;
    • Stephens, Deborah M.;
    • Fitzgerald, Lindsey;
    • Ollila, Thomas;
    • Tabiti, Bukky;
    • Roy, Ishan;
    • Ma, Shuo;
    • Winter, Jane;
    • Pro, Barbara
    Publication type:
    Article